{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T16:01:47Z","timestamp":1783180907510,"version":"3.54.6"},"reference-count":37,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T00:00:00Z","timestamp":1733788800000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4,8]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Hyperuricemia influences lipid metabolism, yet relationships between urate-lowering therapy with allopurinol, serum urate, and lipid levels in patients with chronic kidney disease remain underexplored.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This was a post-hoc analysis of 1970 participants of the CAN AIM to PREVENT who had pre-dialysis chronic kidney disease and were not receiving lipid-lowering therapy or febuxostat. Joint generalized structural equation modeling was used to investigate associations between allopurinol use (yes or no), serum urate [as a continuous or categorical variable (target if &amp;lt;6\u00a0mg\/dl or high if \u22656\u00a0mg\/dl)], and lipid levels [total cholesterol, low-density lipoprotein-cholesterol (LDL-C), high-density lipoprotein cholesterol, and triglycerides) assessed every 6 months for up to 3 years, along with time-to-event outcomes (death or initiation of renal replacement therapy), adjusting for demographic and clinical factors. Mediation analysis was used to determine allopurinol's direct and indirect effects (via urate) on lipid levels.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Allopurinol use independently predicted lower total cholesterol (\u20137.94%, 95% CI: \u221212.13% to \u20133.54%, p\u00a0&amp;lt;\u00a00.001) and LDL-C [\u201313.84% (\u201321.14 to \u20135.87), p\u00a0=\u00a00.001]. Serum urate independently predicted a small increase in LDL-C [0.02% per mg\/dl (0.009 to 0.03), p\u00a0&amp;lt;\u00a00.001]. Patients on allopurinol with target urate had lower LDL-C compared to those not on allopurinol with target urate [\u20134.46% (\u20138.25 to \u20130.50), p\u00a0=\u00a00.027] and those on allopurinol with high urate [\u201310.15% (\u201313.16 to \u20137.04), p\u00a0&amp;lt;\u00a00.001]. Mediation analysis showed that serum urate indirectly mediated only 24% of the effect of allopurinol on LDL-C.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Allopurinol use predicted lower total and especially LDL cholesterol independently of serum urate in this cohort of patients with pre-dialysis chronic kidney disease. Future studies could investigate underlying mechanisms, evaluate clinical implications, and confirm these findings in this and other populations.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ckj\/sfae400","type":"journal-article","created":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T00:33:30Z","timestamp":1733877210000},"source":"Crossref","is-referenced-by-count":2,"title":["Allopurinol use predicts lower low-density lipoprotein cholesterol in patients with pre-dialysis chronic kidney disease\u2014a prospective cohort study"],"prefix":"10.1093","volume":"18","author":[{"given":"Hulya","family":"Taskapan","sequence":"first","affiliation":[{"name":"Research Department, Kidney Life Sciences Institute , Toronto ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haley","family":"Ma","sequence":"additional","affiliation":[{"name":"Research Department, Kidney Life Sciences Institute , Toronto ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berkay","family":"Taskapan","sequence":"additional","affiliation":[{"name":"Research Department, Kidney Life Sciences Institute , Toronto ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Tam","sequence":"additional","affiliation":[{"name":"Research Department, Kidney Life Sciences Institute , Toronto ,","place":["Canada"]},{"name":"Department of Nephrology, The Scarborough Health Network , Toronto ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tabo","family":"Sikaneta","sequence":"additional","affiliation":[{"name":"Research Department, Kidney Life Sciences Institute , Toronto ,","place":["Canada"]},{"name":"Department of Nephrology, The Scarborough Health Network , Toronto ,","place":["Canada"]},{"name":"Department of Medicine, University of Toronto ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,12,9]]},"reference":[{"key":"2025041606022970300_bib1","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1001\/jamainternmed.2018.4463","article-title":"Association of chronic kidney disease with allopurinol use in gout treatment","volume":"178","author":"Vargas-Santos","year":"2018","journal-title":"JAMA Intern Med"},{"key":"2025041606022970300_bib2","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1056\/NEJMra0800885","article-title":"Uric acid and cardiovascular risk","volume":"359","author":"Feig","year":"2008","journal-title":"N Engl J Med"},{"key":"2025041606022970300_bib3","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1111\/j.1523-1755.2005.00273.x","article-title":"Hyperuricemia induces endothelial dysfunction","volume":"67","author":"Khosla","year":"2005","journal-title":"Kidney Int"},{"key":"2025041606022970300_bib4","doi-asserted-by":"publisher","first-page":"F625","DOI":"10.1152\/ajprenal.00140.2005","article-title":"A causal role for uric acid in fructose-induced metabolic syndrome","volume":"290","author":"Nakagawa","year":"2006","journal-title":"Am J Physiol Renal Physiol"},{"key":"2025041606022970300_bib5","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1080\/08037050510008878","article-title":"Effects of allopurinol, a xanthine oxidase inhibitor, on renal injury in hypercholesterolemia-induced hypertensive rats","volume":"14","author":"Minami","year":"2005","journal-title":"Blood Press"},{"key":"2025041606022970300_bib6","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1016\/j.clinbiochem.2017.07.013","article-title":"Effect of allopurinol and uric acid normalization on serum lipids hyperuricemic subjects: a systematic review with meta-analysis","volume":"50","author":"Castro","year":"2017","journal-title":"Clin Biochem"},{"key":"2025041606022970300_bib7","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/BF00270300","article-title":"Serum lipids and lipoproteins in patients with primary gout","volume":"5","author":"Ulreich","year":"1985","journal-title":"Rheumatol Int"},{"key":"2025041606022970300_bib8","doi-asserted-by":"publisher","first-page":"2324","DOI":"10.3390\/nu16142324","article-title":"Effects of xanthine oxidase inhibition by febuxostat on lipid profiles of patients with hyperuricemia: insights from randomized PRIZE study","volume":"16","author":"Saito","year":"2024","journal-title":"Nutrients"},{"key":"2025041606022970300_bib9","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1159\/000479300","article-title":"Fibroblast growth factor 23 predicts mortality and end-stage renal disease in a Canadian Asian population with chronic kidney disease","volume":"137","author":"Jialal","year":"2017","journal-title":"Nephron"},{"key":"2025041606022970300_bib10","doi-asserted-by":"publisher","first-page":"101060","DOI":"10.1016\/j.jhepr.2024.101060","article-title":"Xanthine oxidase promotes hepatic lipid accumulation through high fat absorption by the small intestine","volume":"6","author":"Liu","year":"2024","journal-title":"JHEP Reports"},{"key":"2025041606022970300_bib11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12906-020-03162-5","article-title":"Potential natural inhibitors of xanthine oxidase and HMG-CoA reductase in cholesterol regulation: in silico analysis","volume":"21","author":"Marahatha","year":"2021","journal-title":"BMC Complement Med Ther"},{"key":"2025041606022970300_bib12","doi-asserted-by":"publisher","first-page":"102163","DOI":"10.1016\/j.redox.2021.102163","article-title":"Novel role of xanthine oxidase-dependent H2O2 production in 12\/15-lipoxygenase-mediated de novo lipogenesis, triglyceride biosynthesis and weight gain","volume":"47","author":"Govatati","year":"2021","journal-title":"Redox Biol"},{"key":"2025041606022970300_bib13","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1093\/ckj\/sfz136","article-title":"Spectrum and dosing of urate-lowering drugs in a large cohort of chronic kidney disease patients and their effect on serum urate levels: a cross-sectional analysis from the German Chronic Kidney Disease study","volume":"14","author":"Kielstein","year":"2021","journal-title":"Clin Kidney J"},{"key":"2025041606022970300_bib14","first-page":"1646","article-title":"Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout","volume":"33","author":"Dalbeth","year":"2006","journal-title":"J Rheumatol"},{"key":"2025041606022970300_bib15","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1186\/1471-2474-13-174","article-title":"Prescription and dosing of urate-lowering therapy, rather than patient behaviours, are the key modifiable factors associated with targeting serum urate in gout","volume":"13","author":"Dalbeth","year":"2012","journal-title":"BMC Musculoskelet Disord"},{"key":"2025041606022970300_bib16","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/1471-2369-12-36","article-title":"Chronic kidney disease in gout in a managed care setting","volume":"12","author":"Fuldeore","year":"2011","journal-title":"BMC Nephrol"},{"key":"2025041606022970300_bib17","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1136\/annrheumdis-2016-209707","article-title":"2016 updated EULAR evidence-based recommendations for the management of gout","volume":"76","author":"Richette","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2025041606022970300_bib18","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1002\/acr.24180","article-title":"2020 American College of Rheumatology Guideline for the management of Gout","volume":"72","author":"FitzGerald","year":"2020","journal-title":"Arthritis Care & Research"},{"key":"2025041606022970300_bib19","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1016\/j.kint.2023.10.016","article-title":"Executive summary of the KDIGO 2024 Clinical Practice Guideline for the evaluation and management of chronic kidney disease: known knowns and known unknowns","volume":"105","author":"Levin","year":"2024","journal-title":"Kidney Int"},{"key":"2025041606022970300_bib20","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/0002-9343(84)90743-5","article-title":"Severe allopurinol toxicity","volume":"76","author":"Hande","year":"1984","journal-title":"Am J Med"},{"key":"2025041606022970300_bib21","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1002\/art.30119","article-title":"Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment","volume":"63","author":"Stamp","year":"2011","journal-title":"Arthritis & Rheumatism"},{"key":"2025041606022970300_bib22","doi-asserted-by":"publisher","first-page":"F262","DOI":"10.1152\/ajprenal.00099.2005","article-title":"Dyslipidemia of chronic renal failure: the nature, mechanisms, and potential consequences","volume":"290","author":"Vaziri","year":"2006","journal-title":"Am J Physiol Renal Physiol"},{"key":"2025041606022970300_bib23","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.endonu.2010.06.003","article-title":"Dyslipidemia in renal disease: causes, consequences and treatment","volume":"57","author":"Mesquita","year":"2010","journal-title":"Endocrinolog\u00eda y Nutrici\u00f3n"},{"key":"2025041606022970300_bib24","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1038\/ki.2013.181","article-title":"LDL cholesterol in CKD\u2014to treat or not to treat?","volume":"84","author":"Massy","year":"2013","journal-title":"Kidney Int"},{"key":"2025041606022970300_bib25","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"key":"2025041606022970300_bib26","first-page":"e1046","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the management of blood Cholesterol: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice guidelines","volume":"139","author":"Grundy","year":"2019","journal-title":"Circulation"},{"key":"2025041606022970300_bib27","first-page":"385","article-title":"The effects of lowering uric acid levels using allopurinol on markers of metabolic syndrome in end-stage renal disease patients: a pilot study","volume":"9","author":"Shelmadine","year":"2009","journal-title":"Anadolu Kardiyol Derg"},{"key":"2025041606022970300_bib28","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1007\/s11886-024-02138-y","article-title":"Cardiovascular outcomes of uric acid lowering medications: a meta-analysis","volume":"26","author":"Jamil","year":"2024","journal-title":"Curr Cardiol Rep"},{"key":"2025041606022970300_bib29","doi-asserted-by":"publisher","first-page":"379","DOI":"10.3390\/jcdd10090379","article-title":"Allopurinol for secondary prevention in patients with cardiovascular disease: a systematic review and meta-analysis of randomized controlled trials","volume":"10","author":"Ye","year":"2023","journal-title":"JCDD"},{"key":"2025041606022970300_bib30","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s42000-022-00403-9","article-title":"The effect of allopurinol on cardiovascular outcomes in patients with type 2 diabetes: a systematic review","volume":"21","author":"Bletsa","year":"2022","journal-title":"Hormones"},{"key":"2025041606022970300_bib31","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.ijid.2008.08.014","article-title":"Replication and infectivity of hepatitis B virus in HBV-related glomerulonephritis","volume":"13","author":"Chen","year":"2009","journal-title":"Int J Infect Dis"},{"key":"2025041606022970300_bib32","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1161\/HYPERTENSIONAHA.115.06344","article-title":"Allopurinol and cardiovascular outcomes in adults with hypertension","volume":"67","author":"MacIsaac","year":"2016","journal-title":"Hypertension"},{"key":"2025041606022970300_bib33","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s12872-017-0513-6","article-title":"Allopurinol use and the risk of acute cardiovascular events in patients with gout and diabetes","volume":"17","author":"Singh","year":"2017","journal-title":"BMC Cardiovasc Disord"},{"key":"2025041606022970300_bib34","doi-asserted-by":"publisher","first-page":"2504","DOI":"10.1056\/NEJMoa1915833","article-title":"Effects of allopurinol on the progression of chronic kidney disease","volume":"382","author":"Badve","year":"2020","journal-title":"N Engl J Med"},{"key":"2025041606022970300_bib35","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.atherosclerosis.2018.10.013","article-title":"Effect of low carbohydrate high fat diet on LDL cholesterol and gene expression in normal-weight, young adults: a randomized controlled study","volume":"279","author":"Retterst\u00f8l","year":"2018","journal-title":"Atherosclerosis"},{"key":"2025041606022970300_bib36","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.1002\/art.39813","article-title":"Effects of the dietary approaches to stop hypertension (DASH) diet and sodium intake on serum uric acid","volume":"68","author":"Juraschek","year":"2016","journal-title":"Arthritis & Rheumatology"},{"key":"2025041606022970300_bib37","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1002\/art.41614","article-title":"Effects of dietary patterns on serum urate: results from a randomized trial of the effects of diet on hypertension","volume":"73","author":"Juraschek","year":"2021","journal-title":"Arthritis & Rheumatology"}],"container-title":["Clinical Kidney Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ckj\/advance-article-pdf\/doi\/10.1093\/ckj\/sfae400\/61008277\/sfae400.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/18\/4\/sfae400\/61008277\/sfae400.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/18\/4\/sfae400\/61008277\/sfae400.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T10:02:58Z","timestamp":1744797778000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ckj\/article\/doi\/10.1093\/ckj\/sfae400\/7919744"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,9]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4,8]]}},"URL":"https:\/\/doi.org\/10.1093\/ckj\/sfae400","relation":{},"ISSN":["2048-8505","2048-8513"],"issn-type":[{"value":"2048-8505","type":"print"},{"value":"2048-8513","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,4]]},"published":{"date-parts":[[2024,12,9]]},"article-number":"sfae400"}}